Pharma Companies Use Non-Cash Payments to Lure Staff
Salaries in the U.K. life sciences sector are static, but the range of non-monetary benefits being offered to staff is improving fast, according to a new salary survey.
Salaries in the U.K. life sciences sector are static, but the range of non-monetary benefits being offered to staff is improving fast, according to a new salary survey.
More companies are seeking to recruit and retain employees by focusing on areas like medical cover, gym membership, and life assurance, as they attempt to keep their workforce satisfied while the sector slowly recovers from the recent economic downturn, noted recruitment firm Clinical Professionals.
The report concludes that there has been a slight increase in employee satisfaction, with more than half of those earning at least £49,000 per annum ($80,240) reported as happy with their salary. This represents a slight drop from last year’s crossover point of £50,000. However, over half of respondents in every field of life sciences (other than medical writing) are reported as looking for a new role. This was particularly the case in high-end medical positions.
“The salary survey shows us that, as the war for talent returns to the sector, companies are thinking imaginatively in order to keep their employees satisfied, and rather than raising salaries, improving benefits seems to be a popular option,” said Clinical Professionals’ Group Managing Director, Yvette Cleland.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
